Singapore markets closed
  • Straits Times Index

    -4.83 (-0.15%)
  • S&P 500

    -9.75 (-0.23%)
  • Dow

    -140.35 (-0.41%)
  • Nasdaq

    +22.33 (+0.16%)

    +5,094.25 (+14.24%)
  • CMC Crypto 200

    +45.93 (+4.74%)
  • FTSE 100

    +18.58 (+0.26%)
  • Gold

    -11.90 (-0.63%)
  • Crude Oil

    +0.75 (+1.06%)
  • 10-Yr Bond

    +0.0240 (+1.64%)
  • Nikkei

    +213.07 (+0.74%)
  • Hang Seng

    +103.23 (+0.36%)
  • FTSE Bursa Malaysia

    +7.30 (+0.46%)
  • Jakarta Composite Index

    -15.11 (-0.25%)
  • PSE Index

    +9.70 (+0.14%)

Global Cancer Cachexia Pipeline Insights Market Report 2020 Featuring AEterna Zentaris, Smartfish AS, Tetra Bio-Pharma, Pfizer, Helsinn Healthcare SA, & Lexicon Pharmaceuticals -

·4-min read

The "Cancer Cachexia - Pipeline Insight, 2020" drug pipelines has been added to's offering.

The "Cancer Cachexia - Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Cancer Cachexia pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cancer Cachexia Emerging Drugs Chapters

This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cancer Cachexia Emerging Drugs

Macimorelin: Aeterna Zentaris

Macimorelin stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Zentaris is conducting a pilot clinical trial of repeated doses of macimorelin to assess safety and efficacy in patients with cancer cachexia. The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.

PF- 06946860: Pfizer

Pfizer is conducting a phase 1, randomized, double blind, sponsor-open, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of single-dose, subcutaneous administration of PF 06946860 to healthy adult subjects. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.

Cancer Cachexia: Therapeutic Assessment

This segment of the report provides insights about the different Cancer Cachexia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cancer Cachexia

There are approx. 10+ key companies which are developing the therapies for Cancer Cachexia. The companies which have their Cancer Cachexia drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Tetra Bio-Pharma, Helsinn Healthcare etc.


The report covers around 10+ products under different phases of clinical development like

  • Mid-stage products (Phase II and Phase I/II)

  • Early-stage products (Phase I/II and Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Cancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous

  • Intravenous

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules

  • Amides

  • Proteins and Peptides

  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cancer Cachexia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Cachexia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Cachexia drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Cachexia.

Cancer Cachexia Report Insights

  • Cancer Cachexia Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Cancer Cachexia Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cancer Cachexia drugs?

  • How many Cancer Cachexia drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Cachexia?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cancer Cachexia therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Cancer Cachexia and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • AEterna Zentaris

  • Smartfish AS

  • Tetra Bio-Pharma

  • Pfizer

  • Helsinn Healthcare SA

  • Lexicon Pharmaceuticals

Key Products

  • Macimorelin

  • Remune

  • PPP011

  • PF-06946860

For more information about this drug pipelines report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900